A Phase 2, Open-Label, Multi-Center Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer Subjects Who Have Not Responded to Standard Treatment or Relapsed After Standard Treatment.
Phase of Trial: Phase II
Latest Information Update: 26 Oct 2017
At a glance
- Drugs Amuvatinib (Primary)
- Indications Small cell lung cancer
- Focus Therapeutic Use
- Acronyms ESCAPE
- Sponsors Astex Pharmaceuticals
- 21 Sep 2012 Primary endpoint 'Complete-clinical-response-rate' has not been met.
- 21 Sep 2012 Status changed from active, no longer recruiting to discontinued.
- 19 Sep 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.